Clinical intelligence

Clinical drug trial tracker

Every registered trial behind the experimental drugs we profile: what is reading out next, what has stopped and why, and where results have been posted. Data from ClinicalTrials.gov, retrieved Nov 19, 2026.

Search and filter trials

641 of 641 trials

  1. Phase 4Not yet recruiting

    PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

    Indication
    Clinical pharmacology and supporting studies
    Sponsor
    Massachusetts General Hospital
    Enrollment
    100 (est.)
    Primary completion
    Sep 30, 2029 (est.)
    Registry ID
    NCT07739537
  2. Phase 4Not yet recruiting

    Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation

    Indication
    Obesity and overweight (chronic weight management)
    Sponsor
    Massachusetts General Hospital
    Enrollment
    60 (est.)
    Primary completion
    Jul 31, 2031 (est.)
    Registry ID
    NCT07729332
  3. Phase 4Recruiting

    A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk

    Indication
    Other cancers
    Sponsor
    The First Affiliated Hospital of Zhengzhou University
    Enrollment
    30 (est.)
    Primary completion
    May 24, 2026 (est.)
    Registry ID
    NCT06930573
  4. Phase 3Active, not recruiting

    A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

    Indication
    Elevated lipoprotein(a) with cardiovascular disease
    Sponsor
    Eli Lilly and Company
    Enrollment
    17,300 (est.)
    Primary completion
    Mar 2029 (est.)
    Registry ID
    NCT06292013
  5. Phase 3Active, not recruiting

    Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

    Indication
    Hypercholesterolemia and atherosclerotic cardiovascular disease
    Sponsor
    Merck Sharp & Dohme LLC
    Enrollment
    14,550 (est.)
    Primary completion
    Nov 29, 2029 (est.)
    Registry ID
    NCT06008756
  6. Phase 3Recruiting

    OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events

    Indication
    Elevated lipoprotein(a) with cardiovascular disease
    Sponsor
    Amgen
    Enrollment
    11,000 (est.)
    Primary completion
    Oct 20, 2031 (est.)
    Registry ID
    NCT07136012
  7. Phase 3Recruiting

    MOVE-Lp(a): Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

    Indication
    Elevated lipoprotein(a) with cardiovascular disease
    Sponsor
    Eli Lilly and Company
    Enrollment
    10,450 (est.)
    Primary completion
    Mar 2031 (est.)
    Registry ID
    NCT07157774
  8. Phase 3Active, not recruiting

    The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

    Indication
    Cardiovascular, kidney, liver and other indications
    Sponsor
    Eli Lilly and Company
    Enrollment
    10,000 (est.)
    Primary completion
    Feb 2029 (est.)
    Registry ID
    NCT06383390
  9. Phase 3Active, not recruiting

    PREVAIL: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

    Indication
    Hypercholesterolemia and atherosclerotic cardiovascular disease
    Sponsor
    NewAmsterdam Pharma
    Enrollment
    9,541
    Primary completion
    Nov 2026 (est.)
    Registry ID
    NCT05202509
  10. Phase 3Completed

    Lp(a)HORIZON: Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

    Indication
    Elevated lipoprotein(a) with cardiovascular disease
    Sponsor
    Novartis Pharmaceuticals
    Enrollment
    8,323
    Primary completion
    Jul 16, 2026
    Registry ID
    NCT04023552
  11. Phase 3Active, not recruiting

    Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

    Indication
    Elevated lipoprotein(a) with cardiovascular disease
    Sponsor
    Amgen
    Enrollment
    7,297
    Primary completion
    Mar 31, 2028 (est.)
    Registry ID
    NCT05581303
  12. Phase 3Recruiting

    A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

    Indication
    Cardiovascular, peripheral artery disease and other indications
    Sponsor
    Eli Lilly and Company
    Enrollment
    7,140 (est.)
    Primary completion
    Aug 2031 (est.)
    Registry ID
    NCT07241390
  13. Phase 3Active, not recruiting

    REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

    Indication
    Cardiovascular and other indications
    Sponsor
    Novo Nordisk A/S
    Enrollment
    7,101
    Primary completion
    Sep 1, 2027 (est.)
    Registry ID
    NCT05669755
  14. Phase 3Active, not recruiting

    An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

    Indication
    Elevated lipoprotein(a) with cardiovascular disease
    Sponsor
    Novartis Pharmaceuticals
    Enrollment
    5,700 (est.)
    Primary completion
    Jan 9, 2030 (est.)
    Registry ID
    NCT07517263
  15. Phase 3Enrolling by invitation

    Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

    Indication
    Colorectal cancer
    Sponsor
    Exelixis
    Enrollment
    5,000 (est.)
    Primary completion
    May 31, 2030 (est.)
    Registry ID
    NCT07620574
  16. Phase 3Recruiting

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Indication
    Cardiovascular, kidney, liver and other indications
    Sponsor
    Eli Lilly and Company
    Enrollment
    4,500 (est.)
    Primary completion
    Aug 2030 (est.)
    Registry ID
    NCT07165028
  17. Phase 3Active, not recruiting

    REDEFINE 1: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

    Indication
    Obesity and overweight
    Sponsor
    Novo Nordisk A/S
    Enrollment
    3,400 (est.)
    Primary completion
    Oct 30, 2024
    Registry ID
    NCT05567796
  18. Phase 3Active, not recruitingResults posted

    ATTAIN-1: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

    Indication
    Obesity and overweight (chronic weight management)
    Sponsor
    Eli Lilly and Company
    Enrollment
    3,127
    Primary completion
    Jul 25, 2025
    Registry ID
    NCT05869903
  19. Phase 3Active, not recruiting

    Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

    Indication
    Hypercholesterolemia and atherosclerotic cardiovascular disease
    Sponsor
    Merck Sharp & Dohme LLC
    Enrollment
    3,000 (est.)
    Primary completion
    Oct 13, 2028 (est.)
    Registry ID
    NCT06492291
  20. Phase 3CompletedResults posted

    A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

    Indication
    Hypercholesterolemia and atherosclerotic cardiovascular disease
    Sponsor
    Merck Sharp & Dohme LLC
    Enrollment
    2,912
    Primary completion
    Jul 28, 2025
    Registry ID
    NCT05952856
  21. Phase 3Completed

    ACHIEVE-4: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

    Indication
    Type 2 diabetes
    Sponsor
    Eli Lilly and Company
    Enrollment
    2,749
    Primary completion
    Mar 16, 2026
    Registry ID
    NCT05803421
  22. Phase 3Completed

    REIMAGINE 2: A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

    Indication
    Type 2 diabetes
    Sponsor
    Novo Nordisk A/S
    Enrollment
    2,734
    Primary completion
    Nov 19, 2025
    Registry ID
    NCT06065540
  23. Phase 3CompletedResults posted

    BROADWAY: Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

    Indication
    Hypercholesterolemia and atherosclerotic cardiovascular disease
    Sponsor
    NewAmsterdam Pharma
    Enrollment
    2,530
    Primary completion
    Sep 26, 2024
    Registry ID
    NCT05142722
  24. Phase 3Recruiting

    A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

    Indication
    Obesity and overweight
    Sponsor
    Novo Nordisk A/S
    Enrollment
    2,500 (est.)
    Primary completion
    Feb 23, 2028 (est.)
    Registry ID
    NCT07564414
  25. Phase 3Recruiting

    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    Indication
    Breast cancer
    Sponsor
    Merck Sharp & Dohme LLC
    Enrollment
    2,400 (est.)
    Primary completion
    Mar 23, 2033 (est.)
    Registry ID
    NCT06966700
  26. Phase 3Completed

    TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

    Indication
    Obesity and overweight
    Sponsor
    Eli Lilly and Company
    Enrollment
    2,335
    Primary completion
    Apr 6, 2026
    Registry ID
    NCT05929066
  27. Phase 3Recruiting

    ATTAIN-NOW: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

    Indication
    Obesity and overweight (chronic weight management)
    Sponsor
    Eli Lilly and Company
    Enrollment
    2,001 (est.)
    Primary completion
    Aug 2029 (est.)
    Registry ID
    NCT07794579
  28. Phase 3Completed

    TRIUMPH-3: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

    Indication
    Obesity and overweight
    Sponsor
    Eli Lilly and Company
    Enrollment
    1,946
    Primary completion
    Apr 16, 2026
    Registry ID
    NCT05882045
  29. Phase 3CompletedResults posted

    ACHIEVE-3: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

    Indication
    Type 2 diabetes
    Sponsor
    Eli Lilly and Company
    Enrollment
    1,698
    Primary completion
    Aug 22, 2025
    Registry ID
    NCT06045221
  30. Phase 3CompletedResults posted

    ATTAIN-2: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

    Indication
    Obesity and overweight (chronic weight management)
    Sponsor
    Eli Lilly and Company
    Enrollment
    1,613
    Primary completion
    Aug 8, 2025
    Registry ID
    NCT05872620

Trials that list one of our profiled drugs as an intervention. Status, dates, and enrollment are as reported by sponsors to the registry; “est.” marks anticipated values. For what to look for in a result, read What Is a Primary Clinical Trial Endpoint? and What Is Statistical Significance?

Readout calendar: next 12 months

Active Phase 2 and Phase 3 trials whose primary completion date, the date the last participant is assessed for the main endpoint, falls before Nov 19, 2027. Results are usually announced weeks to months later. Most of these dates are sponsor estimates and often move.

Primary completionTrialDrugPhaseEnrollment
Nov 2026 (est.)PREVAIL · NCT05202509
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
ObicetrapibPhase 39,541
Nov 2026 (est.)TRIUMPH-5 · NCT06662383
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
RetatrutidePhase 3800
Nov 2026 (est.)NCT06448312
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sacituzumab tirumotecanPhase 3406
Nov 2026 (est.)VINCENT · NCT06496243
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
ObicetrapibPhase 269
Dec 2026 (est.)NCT06711900
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Sacituzumab tirumotecanPhase 3432
Dec 2026 (est.)NCT06767527
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
IvonescimabPhase 3416
Dec 2026 (est.)NCT05689853
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
IvonescimabPhase 1/287
Dec 1, 2026 (est.)NCT07070466
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
IvonescimabPhase 240
Dec 2026 (est.)PRO-XL · NCT06568562
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
ZanzalintinibPhase 232
Dec 15, 2026 (est.)STELLAR-304 · NCT05678673
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
ZanzalintinibPhase 3317
Dec 20, 2026 (est.)iTHYM · NCT06750952
Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial
IvonescimabPhase 224
Dec 30, 2026 (est.)VERITAC-3 · NCT05909397
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
VepdegestrantPhase 359
Dec 30, 2026 (est.)NCT05631262
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Sacituzumab tirumotecanPhase 2321
Dec 30, 2026 (est.)NEOINSPIRE · NCT07086326
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
IvonescimabPhase 2164
Dec 30, 2026 (est.)NCT05227664
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
IvonescimabPhase 2120
Dec 30, 2026 (est.)NCT06646055
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
IvonescimabPhase 1/2110
Dec 30, 2026 (est.)NCT07108816
A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)
Sacituzumab tirumotecanPhase 252
Dec 31, 2026 (est.)NCT06081959
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Sacituzumab tirumotecanPhase 3376
Dec 31, 2026 (est.)NCT05229497
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
IvonescimabPhase 1/2154
Dec 31, 2026 (est.)NCT06769971
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
IvonescimabPhase 280
Dec 31, 2026 (est.)NCT06820762
Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
IvonescimabPhase 240
Dec 31, 2026 (est.)NCT07579598
ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma
Sacituzumab tirumotecanPhase 240
Dec 31, 2026 (est.)ZENOBIA · NCT06698250
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
ZanzalintinibPhase 240
Dec 31, 2026 (est.)BALISTA · NCT06793332
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Ivonescimab, Sacituzumab tirumotecanPhase 239
Dec 31, 2026 (est.)NCT06769295
A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
IvonescimabPhase 228
Jan 2027 (est.)NCT06601335
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
IvonescimabPhase 3510
Jan 2027 (est.)MEDICI · NCT07614958
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
ObicetrapibPhase 3426
Jan 2027 (est.)NCT07208773
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
IvonescimabPhase 1/2260
Jan 2027 (est.)NCT06196697
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
IvonescimabPhase 250
Jan 1, 2027 (est.)NCT07561463
Sacituzumab Tirumotecan for Pancreatic Cancer
Sacituzumab tirumotecanPhase 230
Jan 2027 (est.)NCT07623577
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
Sacituzumab tirumotecanPhase 224
Jan 13, 2027 (est.)NCT06951503
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
IvonescimabPhase 3560
Jan 28, 2027 (est.)NCT07385001
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
IvonescimabPhase 1/245
Jan 30, 2027 (est.)NCT07070479
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
IvonescimabPhase 2208
Feb 2027 (est.)ADVANCE · NCT06672549
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
OrforglipronPhase 3125
Feb 1, 2027 (est.)SKB264-ANLO · NCT07388875
Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC
Sacituzumab tirumotecanPhase 230
Feb 28, 2027 (est.)NCT07357220
A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases
IvonescimabPhase 1/272
Feb 28, 2027 (est.)TianjinCIH · NCT07438600
Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC
Sacituzumab tirumotecanPhase 238
Mar 1, 2027 (est.)NCT07011667
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
CagriSemaPhase 3609
Mar 2027 (est.)PROTECT-2 · NCT06992739
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
Sacituzumab tirumotecanPhase 249
Mar 14, 2027 (est.)GZBF · NCT07467447
Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight
RetatrutidePhase 2300
Mar 24, 2027 (est.)NCT05548127
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
VepdegestrantPhase 1/237
Mar 31, 2027 (est.)STAR · NCT07162714
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
IvonescimabPhase 230
Apr 2027 (est.)NCT06279364
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Sacituzumab tirumotecanPhase 3537
Apr 2027 (est.)NCT06925724
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
IvonescimabPhase 250
Apr 15, 2027 (est.)NCT07139470
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
Sacituzumab tirumotecanPhase 1/259
Apr 30, 2027 (est.)NCT06936644
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
IvonescimabPhase 239
May 2027 (est.)NSCLC · NCT06928389
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
IvonescimabPhase 3536
May 2027 (est.)NCT06670196
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Sacituzumab tirumotecanPhase 3420
May 2027 (est.)ACHIEVE-RAM · NCT07613307
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
OrforglipronPhase 3130
May 2027 (est.)NCT06938321
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
IvonescimabPhase 1/2135
May 2027 (est.)NCT07009925
Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.
IvonescimabPhase 238
May 10, 2027 (est.)NCT06074588
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Sacituzumab tirumotecanPhase 3556
May 10, 2027 (est.)NCT07052253
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
IvonescimabPhase 2100
May 11, 2027 (est.)NCT07655570
Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma
IvonescimabPhase 210
May 14, 2027 (est.)NCT06953999
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
IvonescimabPhase 3999
May 30, 2027 (est.)NCT07590531
AMT-116 in Combination With AK112 in Patients With Lung Cancer
IvonescimabPhase 1/2118
May 31, 2027 (est.)NCT05379985
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
DaraxonrasibPhase 1/2754
Jun 2027 (est.)TRIUMPH-8 · NCT07232719
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RetatrutidePhase 3250
Jun 2027 (est.)NCT06162221
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
DaraxonrasibPhase 1/2616
Jun 2027 (est.)NCT06922591
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
DaraxonrasibPhase 1/2183
Jun 1, 2027 (est.)NCT07488572
Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study
IvonescimabPhase 260
Jun 2027 (est.)NCT06848842
Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases
IvonescimabPhase 240
Jun 2027 (est.)NCT07244926
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
Sacituzumab tirumotecanPhase 231
Jun 9, 2027 (est.)NCT07817251
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
CagriSemaPhase 3210
Jun 11, 2027 (est.)NCT05319730
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Sacituzumab tirumotecanPhase 1/2230
Jun 17, 2027 (est.)NCT06980077
Ivonescimab for the Treatment of Thymic Cancer
IvonescimabPhase 225
Jun 20, 2027 (est.)NCT07343479
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
Sacituzumab tirumotecanPhase 245
Jun 30, 2027 (est.)NCT07188103
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
IvonescimabPhase 237
Jun 30, 2027 (est.)NCT07179783
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
Sacituzumab tirumotecanPhase 228
Jul 2027 (est.)NCT07071337
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Sacituzumab tirumotecanPhase 3430
Jul 1, 2027 (est.)NCT07105852
Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
Sacituzumab tirumotecanPhase 259
Jul 1, 2027 (est.)NCT07789444
Sacituzumab Tirumotecan(Sac-TMT) and Brain Radotherapy for EGFR+ NSCLC With Brain Mets
Sacituzumab tirumotecanPhase 253
Jul 1, 2027 (est.)NCT07244965
Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer
IvonescimabPhase 242
Jul 1, 2027 (est.)I-MAC · NCT06805617
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
IvonescimabPhase 235
Jul 1, 2027 (est.)NCT07701122
Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer
Sacituzumab tirumotecanPhase 233
Jul 1, 2027 (est.)NCT07630077
Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities
IvonescimabPhase 230
Jul 10, 2027 (est.)NCT06791148
Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
IvonescimabPhase 245
Jul 11, 2027 (est.)NCT06312176
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Sacituzumab tirumotecanPhase 31,200
Jul 15, 2027 (est.)NCT06537011
AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
IvonescimabPhase 236
Jul 30, 2027 (est.)NCT07258108
Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
Sacituzumab tirumotecanPhase 235
Aug 2027 (est.)NCT06993792
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
OrforglipronPhase 31,400
Aug 2027 (est.)NCT06972459
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
OrforglipronPhase 3800
Aug 2027 (est.)NCT06972472
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
OrforglipronPhase 3600
Aug 2027 (est.)NCT07114315
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
IvonescimabPhase 2160
Aug 1, 2027 (est.)NCT07511504
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
ZanzalintinibPhase 240
Aug 1, 2027 (est.)NCT07088211
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Sacituzumab tirumotecanPhase 239
Aug 1, 2027 (est.)SENIOR-HN · NCT07094685
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
IvonescimabPhase 228
Aug 3, 2027 (est.)SEVILLA · NCT06529718
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
IvonescimabPhase 272
Aug 30, 2027 (est.)NCT07669779
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
IvonescimabPhase 2348
Aug 30, 2027 (est.)NCT06790212
Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer
IvonescimabPhase 2168
Aug 31, 2027 (est.)SKB264-Fru-GA · NCT07689292
Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Sacituzumab tirumotecanPhase 245
Aug 31, 2027 (est.)STAR-01 · NCT07501169
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Sacituzumab tirumotecanPhase 233
Aug 31, 2027 (est.)NCT07329322
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Sacituzumab tirumotecanPhase 230
Sep 1, 2027 (est.)REDEFINE 3 · NCT05669755
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
CagriSemaPhase 37,101
Sep 2027 (est.)NCT06948422
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
OrforglipronPhase 3974
Sep 2027 (est.)TRIUMPH-7 · NCT07035093
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
RetatrutidePhase 3586
Sep 2027 (est.)NCT06948435
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
OrforglipronPhase 3487
Sep 2027 (est.)NCT06952530
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
OrforglipronPhase 3487
Sep 1, 2027 (est.)NCT07591090
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
IvonescimabPhase 2200
Sep 2027 (est.)GRACIE · NCT06846346
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
IvonescimabPhase 288
Sep 30, 2027 (est.)NCT07339839
Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
IvonescimabPhase 1/242
Sep 30, 2027 (est.)NCT07703228
Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC
Sacituzumab tirumotecanPhase 238
Sep 30, 2027 (est.)NCT07229417
A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
IvonescimabPhase 229
Oct 2027 (est.)NCT06686030
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
IvonescimabPhase 2150
Oct 2027 (est.)IVO Lung · NCT07204548
The IVO-LUNG Study
IvonescimabPhase 263
Oct 12, 2027 (est.)NCT07614984
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
EnlicitidePhase 2750
Oct 31, 2027 (est.)NCT07021950
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer
IvonescimabPhase 2130
Nov 2027 (est.)REMBRANDT · NCT06305559
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
ObicetrapibPhase 3300

Stopped trials and why

Sponsors give a short reason when a trial is terminated, suspended, or withdrawn. The reason matters: a safety or efficacy stop means something very different from a business decision. See Why Do Experimental Drugs Fail?

  • OLE · NCT05900141 (Pelacarsen, Phase 3, terminated): “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”
  • NCT07357766 (CagriSema, Phase 3, withdrawn): “The study is withdrawn due to strategic reasons.”
  • NCT07625306 (Pelacarsen, Phase 3, withdrawn): “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”
  • Morpheus Lung · NCT03337698 (Zanzalintinib, Phase 1/2, terminated): “Study was closed early as the sponsor decided not to continue development of certain treatment combinations.”
  • NCT05636267 (Ivonescimab, Phase 1/2, terminated): “Terminated due to sponsor strategic development reprioritization.”
  • NCT05573555 (Vepdegestrant, Phase 1/2, terminated): “Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph 2 and DDI components were not initiated.”
  • NCT06125522 (Vepdegestrant, Phase 1/2, terminated): “Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph2 and DDI components were not initiated.”
  • NCT04999605 (Ivonescimab, Phase 1/2, terminated): “Too low inclusion rate”
  • NCT07357740 (CagriSema, Phase 2, withdrawn): “The study is withdrawn due to strategic reasons.”
  • NCT07038915 (Ivonescimab, Phase 2, withdrawn): “0 participants”
  • NCT07185945 (Zanzalintinib, Phase 2, withdrawn): “Funder withdrew”
  • NCT06191796 (Zanzalintinib, Phase 1, terminated): “The study was terminated prior to starting the Phase 2 portion due to a business decision.”
  • NCT06968988 (Zanzalintinib, Phase 1, suspended): “Protocol amendment”
  • NCT04993664 (Pelacarsen, N/A, withdrawn): “Administrative reason”

Registry data can lag behind company announcements. A trial listed as active may already have reported topline results; check each drug profile for sourced updates. Not medical or investment advice. See our disclaimer.